Mabwell's Injection Gains Approval for Expanded Use in Bone Metastasis and Multiple Myeloma Treatment

Stock News05-20

Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) announced that its wholly-owned subsidiary, Jiangsu Taikang Biological Medicine Co., Ltd., has received approval from the National Medical Products Administration for a supplemental application to expand the indications of Denosumab Injection (brand name: Maiweijian, code: 9MW0321). The approval covers the treatment of bone metastasis in solid tumors and multiple myeloma, aimed at delaying or reducing the risk of skeletal-related events such as pathological fractures, spinal cord compression, radiation to bone, or bone surgery.

The announcement highlights that Maiweijian holds key competitive advantages: firstly, as a biosimilar to Xgeva that was among the first to be launched in China, it benefits from a significant first-mover advantage; secondly, it has demonstrated strong therapeutic efficacy and is recommended in multiple expert consensus documents and treatment guidelines.

Additionally, compared to commonly used clinical treatments like bisphosphonates, Denosumab offers several benefits: 1) It is targeted, specifically binding to RANKL to block the RANKL/RANK/OPG signaling pathway, thereby preventing skeletal-related events in bone metastasis; 2) It shows significantly superior clinical efficacy to bisphosphonates and remains effective even in patients who have not responded to bisphosphonate therapy; 3) It has a favorable safety profile, as it is not cleared by the kidneys, resulting in fewer instances of nephrotoxicity among patients treated with Denosumab.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135264718?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-20 16:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135264718","market":"fut","top_or_hot":-1,"title":"Mabwell's Injection Gains Approval for Expanded Use in Bone Metastasis and Multiple Myeloma Treatment","media":"Stock News","content":"<p>Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) announced that its wholly-owned subsidiary, Jiangsu Taikang Biological Medicine Co., Ltd., has received approval from the National Medical Products Administration for a supplemental application to expand the indications of Denosumab Injection (brand name: Maiweijian, code: 9MW0321). The approval covers the treatment of bone metastasis in solid tumors and multiple myeloma, aimed at delaying or reducing the risk of skeletal-related events such as pathological fractures, spinal cord compression, radiation to bone, or bone surgery.</p>\n<p>The announcement highlights that Maiweijian holds key competitive advantages: firstly, as a biosimilar to Xgeva that was among the first to be launched in China, it benefits from a significant first-mover advantage; secondly, it has demonstrated strong therapeutic efficacy and is recommended in multiple expert consensus documents and treatment guidelines.</p>\n<p>Additionally, compared to commonly used clinical treatments like bisphosphonates, Denosumab offers several benefits: 1) It is targeted, specifically binding to RANKL to block the RANKL/RANK/OPG signaling pathway, thereby preventing skeletal-related events in bone metastasis; 2) It shows significantly superior clinical efficacy to bisphosphonates and remains effective even in patients who have not responded to bisphosphonate therapy; 3) It has a favorable safety profile, as it is not cleared by the kidneys, resulting in fewer instances of nephrotoxicity among patients treated with Denosumab.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mabwell's Injection Gains Approval for Expanded Use in Bone Metastasis and Multiple Myeloma Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMabwell's Injection Gains Approval for Expanded Use in Bone Metastasis and Multiple Myeloma Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-20 16:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) announced that its wholly-owned subsidiary, Jiangsu Taikang Biological Medicine Co., Ltd., has received approval from the National Medical Products Administration for a supplemental application to expand the indications of Denosumab Injection (brand name: Maiweijian, code: 9MW0321). The approval covers the treatment of bone metastasis in solid tumors and multiple myeloma, aimed at delaying or reducing the risk of skeletal-related events such as pathological fractures, spinal cord compression, radiation to bone, or bone surgery.</p>\n<p>The announcement highlights that Maiweijian holds key competitive advantages: firstly, as a biosimilar to Xgeva that was among the first to be launched in China, it benefits from a significant first-mover advantage; secondly, it has demonstrated strong therapeutic efficacy and is recommended in multiple expert consensus documents and treatment guidelines.</p>\n<p>Additionally, compared to commonly used clinical treatments like bisphosphonates, Denosumab offers several benefits: 1) It is targeted, specifically binding to RANKL to block the RANKL/RANK/OPG signaling pathway, thereby preventing skeletal-related events in bone metastasis; 2) It shows significantly superior clinical efficacy to bisphosphonates and remains effective even in patients who have not responded to bisphosphonate therapy; 3) It has a favorable safety profile, as it is not cleared by the kidneys, resulting in fewer instances of nephrotoxicity among patients treated with Denosumab.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688062","symbol_name":"迈威生物-U","start_time":0,"source_url":"","article_id":"1135264718","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135264718","pubTimestamp":1779266432,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) announced that its wholly-owned subsidiary, Jiangsu Taikang Biological Medicine Co., Ltd., has received approval from the National Medical Products...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688062":"迈威生物-U","BK0239":"医药制造","02493":"迈威生物-B","BK1161":"生物科技"},"translate_title":"Mabwell的注射液获批扩大用于骨转移和多发性骨髓瘤治疗","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688062":1,"02493":1},"content_text":"Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) announced that its wholly-owned subsidiary, Jiangsu Taikang Biological Medicine Co., Ltd., has received approval from the National Medical Products Administration for a supplemental application to expand the indications of Denosumab Injection (brand name: Maiweijian, code: 9MW0321). The approval covers the treatment of bone metastasis in solid tumors and multiple myeloma, aimed at delaying or reducing the risk of skeletal-related events such as pathological fractures, spinal cord compression, radiation to bone, or bone surgery.\nThe announcement highlights that Maiweijian holds key competitive advantages: firstly, as a biosimilar to Xgeva that was among the first to be launched in China, it benefits from a significant first-mover advantage; secondly, it has demonstrated strong therapeutic efficacy and is recommended in multiple expert consensus documents and treatment guidelines.\nAdditionally, compared to commonly used clinical treatments like bisphosphonates, Denosumab offers several benefits: 1) It is targeted, specifically binding to RANKL to block the RANKL/RANK/OPG signaling pathway, thereby preventing skeletal-related events in bone metastasis; 2) It shows significantly superior clinical efficacy to bisphosphonates and remains effective even in patients who have not responded to bisphosphonate therapy; 3) It has a favorable safety profile, as it is not cleared by the kidneys, resulting in fewer instances of nephrotoxicity among patients treated with Denosumab.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135264718","isCrawlerRequest":true}